Cargando…

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556722/ https://www.ncbi.nlm.nih.gov/pubmed/34729014 http://dx.doi.org/10.2147/OTT.S343977

Ejemplares similares

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
por: LeVee, Alexis, et al.
Publicado: (2021)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
Publicado: (2019)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]
Publicado: (2018)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
Publicado: (2023)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Corrigendum to “GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)”
Publicado: (2022)

Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”
por: Saltus, Catherine W., et al.
Publicado: (2019)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

Corrigendum to: The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program
Publicado: (2020)

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
Publicado: (2015)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Corrigendum to Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
Publicado: (2019)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib
por: Gong, Lifeng, et al.
Publicado: (2022)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
por: Karzai, Fatima, et al.
Publicado: (2018)

Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States
por: Xu, Chenxia, et al.
Publicado: (2022)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023)

Corrigendum to “The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer”
por: Al-Shamsi, Humaid O., et al.
Publicado: (2017)

Clinical utility of folate-containing oral contraceptives [Corrigendum]
Publicado: (2013)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
por: Kim, Joseph W., et al.
Publicado: (2023)

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

Corrigendum to “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases”
por: Chen, Shuang, et al.
Publicado: (2018)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2022)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
por: Juan Fita, María José, et al.
Publicado: (2023)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
Publicado: (2015)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Clinical experimentation with aerosol antibiotics: current and future methods of administration [Corrigendum]
Publicado: (2014)

Corrigendum to “Clinical Trials of Probiotic Strains in Selected Disease Entities”
por: Dudek-Wicher, Ruth, et al.
Publicado: (2021)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Subcellular Organelle-Targeted Nanostructured Lipid Carriers for the Treatment of Metastatic Breast Cancer [Corrigendum]
Publicado: (2023)

Synergistic Effect Of A Retinoid X Receptor-Selective Ligand Bexarotene And Docetaxel In Prostate Cancer [Corrigendum]
Publicado: (2019)

Family Wellbeing and Sexual Health of Patients Receiving Treatment for Prostate Cancer [Corrigendum]
Publicado: (2023)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d3maigm457jj1hp570gm2u72sq